Spero TherapeuticsSPRO
Recorded

Spero Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration18 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Min LeeBiotech Associate

Innovation Conference. My name is Min Lee, one of the biotech associates here at the firm. It is my pleasure to welcome our next company, Spero Therapeutics. From the company, we have the President and the CEO, Esther Rajavelu. Welcome. Thanks for joining us. Why don't you make some opening comments, Esther? Maybe walk us through your company's recent history, walk us through your company's upcoming catalysts, and then we'll go to some Q&As.

Esther RajaveluPresident and CEO

Yeah, sure. Well, thanks, Min. Thanks for having us here. It's wonderful to participate. Spero Therapeutics is a clinical development company. We just got our first drug approved, and it's partnered with GSK, and now we are moving back to the clinic with our second agent, which is called SP001. It's an anti-CD40 ligand antibody. We in-licensed it from Innovent, announced it in July of this year, and along with it, $105 million non-recourse, non-dilutive funding to really get us into the clinic with this agent. Our lead indication is a rare disease called immunoglobulin G4-related disease, or IgG4-RD. We've guided to starting a phase II trial in that indication in the second quarter of 2027, and our runway is into the second half of 2029.

Esther RajaveluPresident and CEO

We really see this target as one where there are multiple different development opportunities, and we're looking at other development areas as well in addition to IgG4-RD.

Min LeeBiotech Associate

Wonderful. Yeah, we'll go through all of that later. How did you then first go after CD40L in particular? Was there any particular criteria that you guys were looking for when you talked with Innovent?

Esther RajaveluPresident and CEO

Our history has always been in-licensing assets and developing them and then deciding what to do commercially. When we started to look for the next asset as we got line of sight into a regulatory outcome for Utebzi, we were looking at a few different things. We wanted to find a target that was validated with some amount of human data, but not overcrowded and not one that was already approved. We were looking for a molecule that had some features of differentiation versus the competitive market. We also wanted to be able to take that molecule into a few different areas. The potential to deploy it into multiple different therapeutic areas or indications was something that we were interested in as well.

Min LeeBiotech Associate

Great. Okay. Maybe let's first then go through the biology of CD40 real quick. Could you maybe walk us through the history of the CD40L development? As I understand it, there have been some idiosyncratic issues with some of the earlier-gen molecules, like thrombosis, some engineering issues, some manufacturing problems. Then maybe put into perspective of how your lead asset, SP001, actually compared to these early molecules.

Esther RajaveluPresident and CEO

Yeah, sure. Maybe I can start with just a little bit about the target before we get into the history. CD40 ligand is an upstream immune mediator that affects both the T cells, B cells, and the antigen-presenting cells. It has the potential to really address both the innate and the adaptive immune systems. Because of that, we think there are opportunities to target diseases that are really driven by multiple different immune pathways. This target has been in research for a couple decades now. The first-gen molecules, as you say, showed evidence of clinical benefit, but there were some safety burdens, specifically the thromboembolic risk that was highlighted by ruplizumab. It was tied to the Fc region, an active Fc region that then increased the platelet risk.

Esther RajaveluPresident and CEO

Fast-forward to the second-gen molecules, which really avoided that platelet activation risk by just avoiding the antibody format. Fusion proteins and other modalities were developed. Then 001 is what I would characterize as a third-gen molecule, which has a silent Fc region, which theoretically should avoid the thromboembolic risk of the prior generations.

Min LeeBiotech Associate

Got it. This thrombosis risk is tied to the Fc region on the antibody, not the target of CD40 or CD40L, right?

Min LeeBiotech Associate

Yeah, exactly. Perfect. What about the Sanofi molecule, frexalimab?

Min LeeBiotech Associate

I believe you guys do actually have some preclinical data on that online. I think that's also a late-stage anti-CD40L.

Esther RajaveluPresident and CEO

Yeah. So, Innovent had during our diligence, we looked at a lot of the in vitro and in vivo data that Innovent had compiled, and some of these were head-to-head studies with both Amgen's and Sanofi's agents. We do share what Innovent had done, an anti-KLH in vivo mouse model and did a head-to-head study. That study demonstrated that SP001 is more potent than frexalimab, but again, all of this needs to kind of Yeah.

Esther RajaveluPresident and CEO

get demonstrated in the clinic.

Min LeeBiotech Associate

Does that inform anything on dosing at all?

Esther RajaveluPresident and CEO

No. Our dosing decisions are going to be based. I mean, it showed the potency of the molecule, but the dosing decisions would really be based on the healthy volunteer data that Innovent had compiled, as well as the Sjögren's trial that they had. The full sort of compilation of data that we have, both preclinical and clinical, would help us get to the right dose.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day